GlobeNewswire: Supernus Pharmaceuticals, Inc. Contains the last 10 of 274 releaseshttp://www.globenewswire.com/External?Length=42024-03-30T06:08:02ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/06/2841811/0/en/Supernus-to-Participate-in-Two-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=15183Supernus to Participate in Two Upcoming Investor Conferences2024-03-06T21:30:50Z<![CDATA[ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:]]>https://www.globenewswire.com/news-release/2024/02/28/2837486/0/en/Supernus-to-Participate-in-the-TD-Cowen-44th-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=15183Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference2024-02-28T21:30:04Z<![CDATA[ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET at the Marriott Copley Place in Boston, Mass.]]>https://www.globenewswire.com/news-release/2024/02/27/2836455/0/en/Supernus-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=15183Supernus Announces Fourth Quarter and Full Year 2023 Financial Results2024-02-27T21:05:33Z<![CDATA[___________________________________________(1) Total revenues excluding Trokendi XR net product sales is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP). A reconciliation of this measure to Total revenues (GAAP) is included under the heading "Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR net product sales."(2) Operating earnings (non-GAAP) is a non-GAAP measure and is calculated as Operating earnings (loss) (GAAP) plus amortization of intangible assets, share-based compensation, contingent consideration expense (gain), intangible asset impairment charges, and depreciation. A reconciliation of this measure to Operating earnings (loss) (GAAP) is included under the heading "Reconciliation of GAAP Operating earnings (loss) to Non-GAAP Operating earnings."(3) A reconciliation of the operating earnings (non-GAAP) guidance is included under the heading "Full Year 2024 Financial Guidance - GAAP to Non-GAAP Adjustments."]]>https://www.globenewswire.com/news-release/2024/02/13/2828645/0/en/Supernus-Pharmaceuticals-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-Call-on-February-27-2024.html?f=22&fvtc=4&fvtv=15183Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 20242024-02-13T21:05:20Z<![CDATA[ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2023 on Tuesday, February 27, 2024.]]>https://www.globenewswire.com/news-release/2024/02/05/2823531/0/en/Supernus-Wins-Infringement-and-Validity-Case-on-Trokendi-XR-against-Torrent.html?f=22&fvtc=4&fvtv=15183Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent2024-02-05T13:30:39Z<![CDATA[ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the United States District Court for the District of New Jersey ruled that Torrent Pharmaceuticals Ltd. and its subsidiary, Torrent Pharma Inc., infringed U.S. Patent Nos. 8,992,989; 9,549,940; and 9,622,983 by submitting to the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) seeking permission to market a generic version of Trokendi XR® before the expiration of Supernus’ patents.]]>https://www.globenewswire.com/news-release/2023/11/08/2776719/0/en/Supernus-Announces-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=15183Supernus Announces Third Quarter 2023 Financial Results2023-11-08T21:05:44Z<![CDATA[ROCKVILLE, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter of 2023, and associated Company developments.]]>https://www.globenewswire.com/news-release/2023/11/07/2775693/0/en/Supernus-to-Participate-in-the-Jefferies-London-Healthcare-Conference.html?f=22&fvtc=4&fvtv=15183Supernus to Participate in the Jefferies London Healthcare Conference2023-11-07T21:30:42Z<![CDATA[ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023, at 9:00 a.m. ET (2:00 p.m. GMT) at the Waldorf Hilton, London, UK.]]>https://www.globenewswire.com/news-release/2023/11/02/2772111/0/en/Supernus-Announces-SPN-830-Apomorphine-Infusion-Device-NDA-Accepted-for-Review-by-FDA.html?f=22&fvtc=4&fvtv=15183Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA2023-11-02T11:00:05Z<![CDATA[PDUFA Target Action Date of April 5, 2024 PDUFA Target Action Date of April 5, 2024]]>https://www.globenewswire.com/news-release/2023/10/25/2766968/0/en/Supernus-Pharmaceuticals-to-Announce-Third-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-November-8-2023.html?f=22&fvtc=4&fvtv=15183Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 20232023-10-25T20:15:32Z<![CDATA[ROCKVILLE, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2023 after the market closes on Wednesday, November 8, 2023.]]>https://www.globenewswire.com/news-release/2023/10/16/2761108/0/en/Jay-Glazer-Teams-Up-with-Supernus-Pharmaceuticals-to-Raise-Awareness-of-ADHD-and-his-Qelbree-Journey.html?f=22&fvtc=4&fvtv=15183Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey2023-10-16T21:34:21Z<![CDATA[ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3]]>